Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 2Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 16Prostatic Neoplasms 12Advanced Breast Cancer 2Triple Negative Breast Neoplasms 1Patients With T1-4 Advanced Prostate Cancer 1Osteoporosis 1Neoplasm Metastasis 1Inflammatory Breast Neoplasms 1Hot Flashes 1Carcinoma, Lobular 1Breast Diseases 1Breast Cancer Invasive 1Anemia 1

Interventions

Fulvestrant 5Letrozole 4Capecitabine 3pyrotinib 2Paclitaxel 2Goserelin 2Anastrozole 2palbociclib 1olaparib 1neratinib 1liposomal doxorubicin 1exemestane 1entinostat 1ceralasertib 1capivasertib 1Vinorelbine 1Trastuzumab 1Standard of Care 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Injections 1In Situ Hybridization, Fluorescence 1Immunotherapy, Adoptive 1Gonadotropin-Releasing Hormone 1FCN-437c 1Docetaxel 1Decitabine 1Cyclophosphamide 1Combined Modality Therapy 1Cisplatin 1CYH33 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Advanced Breast Cancer × Goserelin × Clear all
NCT05439499 2022-07-06

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Ahon Pharmaceutical Co., Ltd.

Phase 3 Unknown
434 enrolled
Breast

Advanced Breast Cancer

NCT05438810 2022-07-05

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Ahon Pharmaceutical Co., Ltd.

Phase 3 Unknown
312 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡